Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue		$ 25,000		$ 119,000
Costs and expenses:
Cost of revenue		16,000		191,000
Research and development	$ 4,557,000	7,304,000	$ 9,966,000	14,716,000
General and administrative	1,943,000	1,563,000	3,693,000	3,210,000
Total costs and expenses	6,500,000	8,883,000	13,659,000	18,117,000
Loss from operations	(6,500,000)	(8,858,000)	(13,659,000)	(17,998,000)
Other income (expense), net	(1,000)	30,000	9,000	103,000
Loss before provision for income taxes	(6,501,000)	(8,828,000)	(13,650,000)	(17,895,000)
Provision for income taxes	0	0	0	0
Net loss	(6,501,000)	(8,828,000)	(13,650,000)	(17,895,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(6,501,000)	(8,828,000)	(13,650,000)	(17,895,000)
Comprehensive loss	$ (6,501,000)	$ (8,828,000)	$ (13,650,000)	$ (17,895,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.39)	$ (0.77)	$ (0.84)	$ (1.56)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	16,689,399	11,479,294	16,345,211	11,477,521